All-In PodcastE35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, Bitcoin & more
At a glance
WHAT IT’S REALLY ABOUT
Alzheimer’s drug uproar, billionaire space race, and economic fault lines
- This All-In Podcast episode spans Biogen’s controversial Alzheimer’s drug approval, the billionaire-led private space race, post-pandemic work-from-home battles, the housing and inflation crunch, and tax fairness debates. The besties unpack how weak efficacy but strong financial incentives shaped the aducanumab decision and what it reveals about FDA, Medicare, and pharma. They then dive into Bezos vs. Branson vs. SpaceX as a test case for public–private innovation, before shifting to remote work, commercial real estate, and structural problems in housing supply and inflation. The conversation closes with IRS tax leaks, wealth creation mechanics, meritocracy vs. diversity fights, China’s 9-9-6 work culture, and the social psychology behind Bitcoin maximalism.
IDEAS WORTH REMEMBERING
5 ideasAducanumab’s approval exposes tension between scientific rigor, hope, and market incentives.
The FDA overrode a unanimous advisory panel that found the data inconclusive; safety is good but efficacy is modest and contested, yet approval creates a potential $100B market that may spur further Alzheimer’s innovation.
Misaligned healthcare incentives drive up costs even when drug manufacturing is cheap.
The monoclonal antibody reportedly costs around $5 to make per dose yet is priced at ~$56,000 per year, with Medicare Part B paying and physicians getting a 6% ‘spread,’ creating powerful economic pressure to prescribe marginally effective drugs.
Using approvals to ‘create markets’ can accelerate R&D but risks precedent creep.
The hosts argue the FDA may be repeating its Duchenne muscular dystrophy playbook—sanctioning a weak-evidence drug to catalyze industry investment—raising questions about whether regulators should double as market-makers.
The private space race illustrates how government contracting can outperform government-run R&D.
NASA’s shift to buying launch services from SpaceX and others, rather than building everything internally, has cut costs, increased launch cadence, and catalyzed a broader commercial space ecosystem, while also raising real military and geopolitical stakes in orbit.
Hybrid and remote work amplify management, onboarding, and performance-measurement challenges.
Large companies face difficulty supervising thousands of employees they barely see, while startups are leaning into fully distributed models; simple process hacks like daily/weekly Slack check-ins can sharply clarify who’s actually producing.
WORDS WORTH SAVING
5 quotes“If you have a well-structured safety study that says that these things are not harmful to humans, then… we should probably be in the business of getting more drugs approved faster.”
— Chamath Palihapitiya
“The FDA could approve 100 drugs tomorrow, and then what happens to the economics of healthcare if everyone’s allowed to charge any price they want for any care if it has even the slightest range of efficacy?”
— David Friedberg
“This is privatization for the win… Instead of having the government doing all the R&D, you let the private sector do it and NASA contracts with them to deliver the product.”
— David Sacks
“When you lock people out of homeownership, you’re essentially ripping away 60 to 70 percent of how they’re ever going to make real wealth.”
— Chamath Palihapitiya
“We are screaming at each other about things that none of us really understand without taking the time to understand each other. Meanwhile, China is 9-9-6.”
— Chamath Palihapitiya
High quality AI-generated summary created from speaker-labeled transcript.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome